Skip to main content
SpringerLink
Log in

Panipenem/Betamipron

  • Adis Drug Profile
  • Published:
Drugs Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

  • ▴ Panipenem is a parenteral carbapenem antibacterial agent with a broad spectrum of in vitro activity covering a wide range of Gram-negative and Gram-positive aerobic and anaerobic bacteria, including Streptococcus pneumoniae and species producing β-lactamases.

  • ▴ Panipenem is coadministered with betamipron to inhibit panipenem uptake into the renal tubule and prevent nephrotoxicity.

  • ▴ In large, randomised clinical trials, panipenem/ betamipron demonstrated good clinical and bacteriological efficacy (similar to that of imipenem/cilastatin) in adults with respiratory tract or urinary tract infections.

  • ▴ Panipenem/betamipron was also effective in adults with surgical or gynaecological infections, and in paediatric patients with respiratory tract and urinary tract infections in noncomparative trials.

  • ▴ In small trials in elderly patients reported as abstracts, panipenem/betamipron demonstrated clinical efficacy similar to intravenous piperacillin and greater than oral ofloxacin in urinary tract infections. Elderly patients with respiratory tract infections also responded to therapy.

  • ▴ Panipenem/betamipron is well tolerated with few adverse events reported in clinical trials, most commonly elevated serum levels of hepatic transaminases and eosinophils, rash and diarrhoea.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Notes

  1. Use of trade name is for identification purposes only and does not imply product endorsement.

References

  1. Kawamoto I. 1beta-Methylcarbapenem antibiotics. Drags Future 1998; 23(2): 181–9

    Article  CAS  Google Scholar 

  2. Yang Y, Bhachech N, Bush K. Biochemical comparison of imipenem, meropenem and biapenem: permeability, binding to pencillin-binding proteins, and stability to hydrolysis by β-lactamases. J Antimicrob Chemother 1995; 35: 75–84

    Article  PubMed  CAS  Google Scholar 

  3. Balfour JA, Bryson HM, Brogden RN. Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections. Drugs 1996 Jan; 51(1): 99–136

    Article  PubMed  CAS  Google Scholar 

  4. Perry CM, Ibbotson T. Biapenem. Drugs 2002; 62(15): 2221–34; discussion 2235

    Article  PubMed  CAS  Google Scholar 

  5. Hurst M, Lamb HM. Meropenem: a review of its use in patients in intensive care. Drugs 2000 Mar; 59: 653–80

    Article  PubMed  CAS  Google Scholar 

  6. Hikida M, Kawashima K, Yoshida M, et al. Inactivation of new carbapenem antibiotics by dehydropeptidase-I from porcine and human renal cortex. J Antimicrob Chemother 1992 Aug; 30(2): 129–34

    Article  PubMed  CAS  Google Scholar 

  7. Panipenem/betamipron (Carbenin®) prescribing information. Sankyo Co., Ltd. 2001 Jul

  8. Hirouchi Y, Naganuma H, Kawahara Y, et al. Preventive effect of betamipron on nephrotoxicity and uptake of carbapenems in rabbit renal cortex. Jpn J Pharmacol 1994 Sep; 66(1): 1–6

    Article  PubMed  CAS  Google Scholar 

  9. Naganuma H, Tokiwa H, Hirouchi Y, et al. Nephroprotective effect and its mechanism of betamipron (1) — relationships of renal transport [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 166–77

    CAS  Google Scholar 

  10. Enomoto A, Takeda M, Shimoda M, et al. Interaction of human organic anion transporters 2 and 4 with organic anion transport inhibitors. J Pharmacol Exp Ther 2002; 301(3): 797

    Article  PubMed  CAS  Google Scholar 

  11. Miyadera T, Sugimura Y, Oida S, et al. CS-976 (Panipenem/ Betamipron), a new carbapenem antibiotic. Sankyo Kenky-usho Nempo 1991; 43(3): 1–73

    CAS  Google Scholar 

  12. Japanese Society of Chemotherapy. Committee for Revision of IC Determination Method. Breakpoint of antimicrobials for the treatment of respiratory tract infections and sepsis, supplement of new and existing antimicrobials [in Japanese]. Jpn J Chemother 1997 Sep; 45(9): 757–61

    Google Scholar 

  13. Inoue K, Hamana Y, Mitsuhashi S. Antibacterial activity of panipenem, a new carbapenem antibiotic [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 1–13

    CAS  Google Scholar 

  14. Higa F, Irabu Y, Fukuhara H, et al. Laboratory and clinical studies on panipenem/betamipron [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 449–54

    Google Scholar 

  15. Goto Y, Ichimiya T, Ikuta M, et al. In vitro antibacterial activity of panipenem/betamipron, a carbapenem antibiotic, and its clinical study in respiratory airway infections [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 441–8

    Google Scholar 

  16. Goto T, Makinose S, Kawahara M, et al. Antimicrobial activity and clinical evaluation of panipenem/betamipron in urinary tract infections [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 512–20

    Google Scholar 

  17. Nomura S, Nagayama A. In vitro antibacterial activity of S-4661, a new parenteral carbapenem, against urological pathogens isolated from patients with complicated urinary tract infections. J Chemother 2002 Apr; 14(2): 155–60

    PubMed  CAS  Google Scholar 

  18. Ohishi A, Takita M, Suzuki E, et al. Basic and clinical studies on panipenem/betamipron [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 339–49

    Google Scholar 

  19. Furugo I, Takii M, Ueda M, et al. Microbiological and clinical studies of Haemophilus influenzae isolated at Kitakyushu Municipal Medical Center from 1996 through 1999 [in Japanese]. Jpn J Antibiot 2002 Jun; 55(3): 302–10

    PubMed  Google Scholar 

  20. Matsuo Y. In vitro susceptibilities to 23 antimicrobial agents of Haemophilus influenzae from pediatric patients in Japan. Kurame Med J 2000; 47(3): 205–10

    Article  CAS  Google Scholar 

  21. Miyazaki S, Fujikawa T, Kanazawa K, et al. In vitro and in vivo activities of meropenem and comparable antimicrobial agents against Haemophilus influenzae, including beta-lactamase-negative ampicillin-resistant strains. J Antimicrob Chemother 2001 Nov; 48(5): 723–6

    Article  PubMed  CAS  Google Scholar 

  22. Watanabe A, Tokue Y, Takahashi H, et al. Comparative in-vitro activity of carbapenem antibiotics against respiratory pathogens isolated between 1999 and 2000. J Infect Chemother 2001 Dec; 7(4): 267–71

    Article  PubMed  CAS  Google Scholar 

  23. Hikida M, Terashima S, Sato Y, et al. Comparative antibacterial activity of carbapenems against P. aeruginosa (1) [in Japanese]. Jpn J Antibiot 2001 Nov; 54(11): 571–9

    PubMed  CAS  Google Scholar 

  24. Kato K, Iwai S, Kumasaka K, et al. Survey of antibiotic resistance in Pseudomonas aeruginosa by The Tokyo Johoku Association of Pseudomonas Studies. J Infect Chemother 2001 Dec; 7(4): 258–62

    Article  PubMed  CAS  Google Scholar 

  25. Fukuoka T, Ohya S, Narita T, et al. Activity of the carbapenem panipenem and role of the OprD (D2) protein in its diffusion through the Pseudomonas aeruginosa outer membrane. Antimicrob Agents Chemother 1993 Feb; 37(2): 322–7

    Article  PubMed  CAS  Google Scholar 

  26. Fukuoka T, Masuda N, Takenouchi T, et al. Increase in susceptibility of Pseudomonas aeruginosa to carbapenem antibiotics in low-amino-acid media. Antimicrob Agents Chemother 1991 Mar; 35: 529–32

    Article  PubMed  CAS  Google Scholar 

  27. Ishii C, Kakuta M, Abe T, et al. Rapid bactericidal activities of carbapenems against Pseudomonas aeruginosa in simulating human plasma concentrations [in Japanese]. Jpn J Antibiot 2002 Apr; 55(2): 187–95

    PubMed  CAS  Google Scholar 

  28. Nagai K, Matsuo Y, Tsumura N, et al. Antimicrobial susceptibilities and serotypes of Streptococcus pneumoniae in south-western Japan and correlation of penicillin-binding protein 2b and 2x mutations in susceptibilities of penicillin G and cefotaxime. Diagn Microbiol Infect Dis 2000 Jun; 37(2): 107–13

    Article  PubMed  CAS  Google Scholar 

  29. Fukuoka T, Inoue H, Abe T, et al. In vitro and in vivo activities of panipenem against penicillin-resistant Streptococcus pneumoniae [in Japanese]. Jpn J Antibiot 2001 Jul; 54(7): 365–71

    PubMed  CAS  Google Scholar 

  30. Yonezu S, Yasunaga K, Ueda Y. Laboratory and clinical studies on panipenem/betamipron [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 385–93

    Google Scholar 

  31. Ishihara S, Yasuda M, Tada K, et al. Clinical studies and antibiotic sensitivities of Enterococcus faecalis isolated from complicated urinary tract infection [in Japanese]. Jpn J Chemother 1995 Apr; 43: 451–6

    CAS  Google Scholar 

  32. Hayashi I, Onuma K, Hasuike M. Panipenem/betamipron: antibacterial activity against Staphylococcus aureus and clinical efficacy in respiratory tract infection [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 333–8

    Google Scholar 

  33. Utsui Y, Ohya S, Domon H, et al. Microbiological evaluation of panipenem/betamipron, a new parenterally active carbapenem. I. In vitro antibacterial activities [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 83–101

    CAS  Google Scholar 

  34. Goto S, Katsuta M, Miyazaki S, et al. Antibacterial activity of panipenem/betamipron, a new carbapenem [in Japanese]. Chemotherapy 1991; 39 Suppl. 3

  35. Totsuka K, Kikuchi K, Shibata Y, et al. Study on postantibiotic effect (PAE) of panipenem/betamipron, a carbapenem antibiotic [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 78–82

    CAS  Google Scholar 

  36. Nakashima M, Uematsu T, Kanamaru M, et al. Phase I study of panipenem/betamipron II — multiple dose study [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 265–88

    CAS  Google Scholar 

  37. Nakashima M, Uematsu T, Kanamaru M, et al. Phase I study of panipenem/betamipron I — single dose study [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 242–64

    CAS  Google Scholar 

  38. Fujii R, Abe T, Tajima T, et al. Overall clinical evaluation of panipenem/betamipron against infections in pediatric field [in Japanese]. Jpn J Antibiot 1992 Feb; 45(2): 208–27

    PubMed  CAS  Google Scholar 

  39. Aoki N, Usuda Y, Koda Y, et al. Clinical pharmacology and efficacy of panipenem/betamipron [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 372–84

    Google Scholar 

  40. Kurata K. Investigation of panipenem/betamipron levels in sera and various tissues in patients of orthopedic surgery [in Japanese]. Jpn J Antibiot 1992 Feb; 45(2): 155–9

    PubMed  CAS  Google Scholar 

  41. Suzuki K, Horiba M, Naide Y, et al. Clinical study on panipenem/betamipron in bacterial prostatitis [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 773–7

    Google Scholar 

  42. Yamamoto T, Yasuda J, Iwasaku K, et al. Basic and clinical studies on panipenem/betamipron in obstetrics and gynecology [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 636–46

    Google Scholar 

  43. Yamanaka M, Miyagi E, Ooyama T, et al. Fundamental and clinical studies on panipenem/betamipron in obstetrics and gynecology [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 628–35

    Google Scholar 

  44. Ishikawa M, Ishikawa M, Shimizu T, et al. Fundamental and clinical studies of panipenem/betamipron in obstetrics and gynecology [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 609–14

    Google Scholar 

  45. Tanimura H, Ochiai M, Sugimoto Y, et al. Tissue concentrations and clinical efficacy of panipenem/betamipron in surgical infections [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 585–95

    Google Scholar 

  46. Yura J, Shinagawa N, Ishikawa S, et al. Fundamental and clinical studies of panipenem/betamipron in surgery [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 557–71

    Google Scholar 

  47. Takahashi A, Takasugi M, Utsunomiya Y, et al. Laboratory and clinical evaluation of panipenem/betamipron, a new carbapenem antibiotic [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 428–40

    Google Scholar 

  48. Takagi S, Maeda H, Goto K, et al. Fundamental and clinical studies on panipenem/betamipron in urology [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 484–93

    Google Scholar 

  49. Naganuma H, Hirouchi Y, Kawahara Y, et al. Nephroprotective effect and its mechanism of betamipron (2) — relationships of renal excretion [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 178–89

    CAS  Google Scholar 

  50. Ohashi A, Togawa A, Hishikawa A, et al. Pharmacokinetic study on panipenem/betamipron in patients with end-stage renal disease [in Japanese]. Jpn J Clin Pharmacol Ther 2003; 34(1): 17S–8S

    Article  Google Scholar 

  51. Nagai K, Shimizu T, Togo A, et al. Decrease in serum levels of valproic acid during treatment with a new carbapenem, panipenem/betamipron [letter]; [in Japanese]. J Antimicrob Chemother 1997 Feb; 39(2): 295–6

    Article  PubMed  CAS  Google Scholar 

  52. Yamagata T, Momoi MY, Murai K, et al. Panipenem-betamipron and decreases in serum valproic acid concentration. Ther Drug Monit 1998 Aug; 20(4): 396–400

    Article  PubMed  CAS  Google Scholar 

  53. Yamamura N, Imura K, Naganuma H, et al. Panipenem, a carbapenem antibiotic, enhances the glucuronidation of intravenously administered valproic acid in rats. Drug Metab Dispos 1999 Jun; 27(6): 724–30

    PubMed  CAS  Google Scholar 

  54. Kojima S, Nadai M, Kitaichi K, et al. Possible mechanism by which the carbapenem antibiotic panipenem decreases the concentration of valproic acid in plasma in rats. Antimicrob Agents Chemother 1998 Dec; 42(12): 3136–40

    PubMed  CAS  Google Scholar 

  55. Torii M, Takiguchi Y, Izumi M, et al. Carbapenem antibiotics inhibit valproic acid transport in Caco-2 cell monolayers. Int J Pharm 2002 Feb 21; 233(1–2): 253-6

    Article  PubMed  CAS  Google Scholar 

  56. Shimada J, Hori S, Kanemitsu K, et al. A comparative study on the convulsant activity of carbapenems and beta-lactams. Drugs Exp Clin Res 1992; 18(9): 377–81

    PubMed  CAS  Google Scholar 

  57. Sunagawa M, Matsumura H, Sumita Y, et al. Structural features resulting in convulsive activity of carbapenem compounds: effect of C-2 side chain. J Antibiot (Tokyo) 1995 May; 48(5): 408–16

    Article  CAS  Google Scholar 

  58. Kurihara A, Hisaoka M, Mikuni N, et al. Neurotoxicity of panipenem/betamipron, a new carbapenem, in rabbits: correlation to concentration in central nervous system. J Pharmacobiodyn 1992 Jul; 15(7): 325–32

    Article  PubMed  CAS  Google Scholar 

  59. Kobayashi Y, Kanishi Y, Noda S, et al. Effectiveness of panipenem/betamipron for infections in gynecological cancer patients [abstract no. P337]. J Antimicrob Chemother 1999 Jul; 44 Suppl. A: 114

    Google Scholar 

  60. Nakamura J, Fujita K, Okimoto N, et al. The study of a combination therapy of panipenem/betamipron (PAP/BP) and clindamycin (CLDM) for treatment of respiratory tract infections in elderly patients [abstract no. 3337]. 20th International Congress of Chemotherapy; 1997 Jun 29–Jul 3; Sydney, 105

  61. Ishioka T. Comparative evaluation of panipenam/betamipron and ofloxacin on urinary tract infection in the elderly [abstract no. W128]. First European Congress of Chemotherapy; 1996 May 14; Glasgow

  62. Ishioka T. Comparative evaluation of panipenem/betamipron and piperacillin on urinary tract infection in the elderly [abstract no. 114.025]. 7th International Congress for Infectious Diseases; 1996 Jun 10; Hong Kong, 300

  63. Hara K, Hiraga Y, Omichi M, et al. A comparative study of panipenem/betamipron and imipenem/cilastatin in bacterial pneumonia [in Japanese]. Chemotherapy 1992; 40(4): 509–31

    Google Scholar 

  64. Hara K, Kouno S KH, Takebe K, et al. A comparative study of panipenem/betamipron and imipenem/cilastatin in respiratory tract infections [in Japanese]. Chemotherapy 1992; 40(5): 613–37

    Google Scholar 

  65. Kumazawa J, Matsumoto T, Kumamoto Y, et al. Phase III comparative clinical trial of panipenem/betamipron (PAPM/ BP) with imipenem/cilastatin sodium (IPM/CS) in complicated urinary tract infections [in Japanese]. Nishinihon J Urol 1992; 54(2): 254–71

    Google Scholar 

  66. Hara K, Kohno S, Koga H, et al. Dose finding study on panipenem/betamipron in bacterial pneumonia [in Japanese]. Chemotherapy 1992; 40(3): 348–66

    Google Scholar 

  67. Matsumoto T, Ogata N, Mizunoe Y, et al. Fundamental and clinical studies of panipenem/betamipron in the urological field [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 504–11

    Google Scholar 

  68. Inatsuchi H, Masuda A, Arihara K, et al. Fundamental and clinical studies on panipenem/betamipron in urology [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 469–75

    Google Scholar 

  69. Chimura T, Oda T, Saito N, et al. Change of cytokines and clinical efficacy of panipenem/betamipron in obstetric and gynecological infections. Yamagata Study Group of Panipenem/Betamipron in Obstetric and Gynecological Infections [in Japanese]. Jpn J Antibiot 1998 Jan; 51(1): 37–45

    CAS  Google Scholar 

  70. Hirabayashi K, Okada E. Clinical study on panipenem/ betamipron in obstetrics and gynecology [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 810–3

    Google Scholar 

  71. Manzai M, Ikuta K, Nakaya T, et al. Panipenem/betamipron in obstetrics and gynecology [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 807–9

    Google Scholar 

  72. Chimura T, Tezuka N, Oda T, et al. Panipenem/betamipron in obstetrics and gynecology [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 800–3

    Google Scholar 

  73. Cho N, Fukunaga K, Kunii K. Pharmacokinetics and clinical studies of panipenem/betamipron in obstetrics and gynecology [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 615–21

    Google Scholar 

  74. Tsuyuki K, Arisawa Y, Yokoyama I, et al. Studies on the efficacy and safety of panipenem/betamipron in infections in surgical domain and the safety when mixed with lactate containing infusion [in Japanese]. Jpn J Antibiot 1992 Feb; 45(2): 188–96

    PubMed  CAS  Google Scholar 

  75. Nakayama I, Yamaji E, Kawamura H, et al. Study on surgical infections, especially intra-abdominal infections, postoperative infections, and skin and soft tissue infections: clinical application of panipenem/betamipron, a new carbapenem antibiotic for injection [in Japanese]. Chemotherapy 1991; 39 Suppl. 3: 534–51

    Google Scholar 

  76. Shibuya Y, Kitamura S, Tani G, et al. Evaluation of panipenem/ betamipron (PAPM/BP) in pneumonia in elderly patients. J Infect Chemother 2002 Jun; 8(2): 151–4

    Article  PubMed  CAS  Google Scholar 

  77. Goto H, Inamatsu T, Sano Y, et al. Evaluation of a multi-hospital cooperative study on the efficacy and safety of panipenem/betamipron (PAPM/BP) on elderly patients of respiratory infections [in Japanese]. Kansenshogaku Zasshi 1999 Jan; 73(1): 43–52

    PubMed  CAS  Google Scholar 

  78. Shimada K, Goto H, Inamatsu T, et al. Efficacy and safety of panipenem/betamipron in respiratory infection of aged people [abstract no. 3333]. 20th International Congress of Chemotherapy; 1997 Jun 29–Jul 3; Sydney, 104

  79. Kato T, Goshima T, Akita H, et al. Clinical and bacteriological studies on panipenem/betamipron in pediatrics. Kanagawa Research Group for Infectious Diseases of Children [in Japanese]. Jpn J Antibiot 1998 Apr; 51(4): 286–97

    CAS  Google Scholar 

  80. Anonymous. Discussion on the safety of panipenem/betamipron according to postmarketing surveillance [in Japanese]. Jpn J Chemother 1999; 47 (7): 396–410

  81. Katsuki K, Shinohara K, Yamada T. A case of fatal seizure and unconsciousness caused by panipenem/betamipron [in Japanese]. Kansenshogaku Zasshi 1998 Jun; 72(6): 651–3

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand

    Karen L. Goa & Stuart Noble

Authors
  1. Karen L. Goa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stuart Noble
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Karen L. Goa.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Goa, K.L., Noble, S. Panipenem/Betamipron. Drugs 63, 913–925 (2003). https://doi.org/10.2165/00003495-200363090-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200363090-00005

Keywords

Search

Navigation